These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32698705)

  • 1. Trial designs for evaluating combination HIV prevention approaches.
    Chen YQ; Peng L; Wang Y; Appelmans E; Dasgupta S; Fleming TR
    HIV Res Clin Pract; 2020; 21(2-3):72-82. PubMed ID: 32698705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
    Johnson WD; Diaz RM; Flanders WD; Goodman M; Hill AN; Holtgrave D; Malow R; McClellan WM
    Cochrane Database Syst Rev; 2008 Jul; (3):CD001230. PubMed ID: 18646068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An examination of effect estimation in factorial and standardly-tailored designs.
    Allore HG; Murphy TE
    Clin Trials; 2008; 5(2):121-30. PubMed ID: 18375650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distributive randomization: a pragmatic fractional factorial design to screen or evaluate multiple simultaneous interventions in a clinical trial.
    Haviari S; Mentré F
    BMC Med Res Methodol; 2024 Mar; 24(1):64. PubMed ID: 38468221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multilevel factorial experiments for developing behavioral interventions: power, sample size, and resource considerations.
    Dziak JJ; Nahum-Shani I; Collins LM
    Psychol Methods; 2012 Jun; 17(2):153-75. PubMed ID: 22309956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis.
    Wolbers M; Heemskerk D; Chau TT; Yen NT; Caws M; Farrar J; Day J
    Trials; 2011 Feb; 12():26. PubMed ID: 21288326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.
    White IR; Choodari-Oskooei B; Sydes MR; Kahan BC; McCabe L; Turkova A; Esmail H; Gibb DM; Ford D
    Clin Trials; 2022 Aug; 19(4):432-441. PubMed ID: 35579066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factorial design considerations.
    Green S; Liu PY; O'Sullivan J
    J Clin Oncol; 2002 Aug; 20(16):3424-30. PubMed ID: 12177102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety interventions for the prevention of accidents at work: A systematic review.
    Dyreborg J; Lipscomb HJ; Nielsen K; Törner M; Rasmussen K; Frydendall KB; Bay H; Gensby U; Bengtsen E; Guldenmund F; Kines P
    Campbell Syst Rev; 2022 Jun; 18(2):e1234. PubMed ID: 36911341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal trial design selection: a comparative analysis between two-arm and three-arm trials incorporating network meta-analysis for evaluating a new treatment.
    Ye F; Wang C; O'Connor AM
    BMC Med Res Methodol; 2023 Nov; 23(1):267. PubMed ID: 37951877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments.
    Jaki T; Vasileiou D
    Stat Med; 2017 Feb; 36(4):563-580. PubMed ID: 27804166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of agent-based simulations to design and interpret HIV clinical trials.
    Cuadros DF; Abu-Raddad LJ; Awad SF; García-Ramos G
    Comput Biol Med; 2014 Jul; 50():1-8. PubMed ID: 24792492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifiability of Components of Complex Interventions Using Factorial Designs.
    Gleiss A
    J Altern Complement Med; 2017 Aug; 23(8):569-574. PubMed ID: 28731782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-factorial analyses of two-by-two factorial trial designs.
    Korn EL; Freidlin B
    Clin Trials; 2016 Dec; 13(6):651-659. PubMed ID: 27439306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Design Approaches for HIV Prevention Efficacy Trials.
    Prudden HJ; Tatoud R; Janes H; Wallace S; Miller V; Bekker LG; Donnell D
    AIDS Res Hum Retroviruses; 2024 May; 40(5):301-307. PubMed ID: 37392020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When should factorial designs be used for late-phase randomised controlled trials?
    White IR; Szubert AJ; Choodari-Oskooei B; Walker AS; Parmar MK
    Clin Trials; 2024 Apr; 21(2):162-170. PubMed ID: 37904490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size calculations for group randomized trials with unequal group sizes through Monte Carlo simulations.
    Shi Y; Lee JH
    Stat Methods Med Res; 2018 Sep; 27(9):2569-2580. PubMed ID: 30103663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.